The past three decades of the ADC development have provided us seven approved ADCs and there is new momentum in the ADC cancer therapeutics development. But unfortunately, the vast majority of ADCs have been terminated during and prior toclinical development. This workshop will be providing a comprehensive review of the ADC landscape, including early and late-stage ADCs and trends in next-generation ADC development. Major learnings from successful as well as failed targets, linkers, site-specific conjugation, cytotoxic warheads, and translational strategies will be discussed.

Gain in-depth insights into:

• Navigating of the ADC World
• Learning from targets for solid and heme tumors
• Linkers and conjugation matter
• Learnings from antibody selection for ADCs
• Translational medicine lessons

Rakesh Dixit, Chief Executive Officer & Founder, BioNavigen

Tumor Blood Vessels as Targets for Cancer Therapy – Presented by Kyoko Hida Cancer Stromal Targeting Therapy – Presented by Yasuhiro Matsumura Developments of antibody-drug conjugate against tissue factor - Presented by Ryo Tsumura

In this workshop, we will:

• Investigate the biological effects of anti-tissue factor ADC in stroma-rich mouse model
• Evaluate the relationship between binding kinetics and tumor penetration ability
• Demonstrate the efficacy of anti-tissue factor ADC in several tumor models

Trastuzumab Deruxtecan (T-DXd, DS-8201a): An Overview of Pharmacology, Clinical Pharmacology, and Clinical Activity – Presented by Ronald Fleming

• Overview of the pharmacology of T-DXd
• Clinical pharmacology of T-DXd in cancer patients
• Summary of clinical studies in cancer patients

Ryo Tsumura, Research Scientist,National Cancer Centre
Kyoko Hida, Professor, University of Hokkaido
Ronald Fleming, Executive Director, Oncology Clinical Development, Daiichi Sankyo
Yasuhiro Matsumura, Director,National Cancer Centre

This workshop is designed to accommodate both attendees new to modelling and simulation as well as researchers more seasoned in ADC development.

This session will introduce basic tenets of antibody drug conjugate PK/PD and how to characterize these aspects using empirical and systemsbased mathematical models.

These models include systemic PK (plasma clearance, payload deconjugation, target mediated drug distribution, etc.), tissue distribution (e.g. heterogeneous tumor concentrations), and cellular targeting (internalization, payload release, bystander effects, etc.).

Several hands-on modelling examples will be conducted along with strengths and limitations of these approaches.